ArticleJNCI cancer spectrum2025

Leveraging real-world evidence to personalize adjuvant therapy in HR+/HER2- early breast cancer.

Yael Bar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.